24.93
-1.20 (-4.59%)
| Penutupan Terdahulu | 26.13 |
| Buka | 25.90 |
| Jumlah Dagangan | 497,224 |
| Purata Dagangan (3B) | 1,419,554 |
| Modal Pasaran | 4,217,702,912 |
| Harga / Pendapatan (P/E TTM) | 16.08 |
| Harga / Pendapatan (P/E Ke hadapan) | 39.68 |
| Harga / Jualan (P/S) | 4.14 |
| Harga / Buku (P/B) | 4.74 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | 22.97% |
| Margin Operasi (TTM) | 7.90% |
| EPS Cair (TTM) | 1.37 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 14.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.32% |
| Nisbah Semasa (MRQ) | 2.88 |
| Aliran Tunai Operasi (OCF TTM) | 148.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 19.27 M |
| Pulangan Atas Aset (ROA TTM) | 5.56% |
| Pulangan Atas Ekuiti (ROE TTM) | 37.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | ACADIA Pharmaceuticals Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
|
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.57% |
| % Dimiliki oleh Institusi | 104.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rtw Investments, Lp | 30 Sep 2025 | 7,144,524 |
| Palo Alto Investors Lp | 30 Sep 2025 | 2,466,684 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (UBS, 60.45%) | Beli |
| Median | 31.50 (26.35%) | |
| Rendah | 25.00 (Stifel, 0.28%) | Pegang |
| Purata | 32.38 (29.88%) | |
| Jumlah | 6 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 25.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 06 Jan 2026 | 36.00 (44.40%) | Beli | 26.94 |
| UBS | 06 Jan 2026 | 40.00 (60.45%) | Beli | 26.94 |
| HC Wainwright & Co. | 15 Dec 2025 | 37.00 (48.42%) | Beli | 27.26 |
| Stifel | 11 Dec 2025 | 25.00 (0.28%) | Pegang | 26.68 |
| Mizuho | 02 Dec 2025 | 29.00 (16.33%) | Pegang | 25.43 |
| JP Morgan | 17 Nov 2025 | 31.00 (24.35%) | Beli | 24.01 |
| Needham | 06 Nov 2025 | 29.00 (16.33%) | Beli | 21.65 |
| RBC Capital | 06 Nov 2025 | 32.00 (28.36%) | Beli | 21.65 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2026 | Pengumuman | Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference |
| 18 Dec 2025 | Pengumuman | Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 |
| 12 Dec 2025 | Pengumuman | Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome |
| 20 Nov 2025 | Pengumuman | Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference |
| 05 Nov 2025 | Pengumuman | Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |